Expanding sales of voice input services for the medical and nursing care sectors and pursuing a partner strategy
First written in FY2017-Q1. 27 of 34 entries say "Advanced", first in FY2018. Latest entry: 2026-08-14.
No other company in this theme has enough history to compare yet.
- 2026-08-14AdvancedEarnings
「Sales of the flagship AI voice-input software AmiVoice® Ex7 series and the medical AI speech recognition work-sharing service AmiVoice® iNote progressed steadily.」
Steady sales of the flagship medical products continued, and cumulative licenses increased from 68,991 at the end of the previous fiscal year to 69,444. - FY2026AdvancedAnnual report
「As efforts to optimize physicians' working hours expand against the backdrop of physicians' work-style reform, demand is increasing at hospitals for improved efficiency among physicians, nurses and other medical professionals. Sales of our flagship AI voice-input software, the AmiVoice® Ex7 series, and use of the medical AI speech recognition work-sharing service AmiVoice® iNote progressed steadily.」
Sales and use of Ex7 and iNote for the medical sector progressed steadily, and the company also improved iNote's user interface to suit users' situations. - 2026-05-13AdvancedRevision of earnings forecasts
「As efforts to optimize physicians' working hours expand against the backdrop of physicians' work-style reform, demand is increasing at hospitals for improved efficiency among physicians, nurses and other medical professionals. Sales of our flagship AI voice-input software, the AmiVoice® Ex7 series, and use of the medical AI speech recognition work-sharing service AmiVoice® iNote progressed steadily.」
Sales of the Ex7 series and use of iNote progressed steadily, and the Medical Division increased both revenue and profit. - FY2026-H1AdvancedAnnual report
「Sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector remained strong. The company also began promoting market adoption of "AmiVoice® AI Agent," a service that improves operational efficiency by having AI perform mouse and keyboard operations at the appropriate time and place in response to voice prompts. Stock ratio: 52.5% at the end of the first quarter → 47.5% at the end of the interim period; licenses (cumulative): 66,434 at the end of the first quarter → 66,773 at the end of the interim period」
Sales of Ex7 and iNote remained strong, and the company began and continued promoting market adoption of AI Agent. The cumulative number of licenses increased from 66,434 to 66,773, while the stock ratio declined from 52.5% to 47.5%. - FY2025AdvancedAnnual report
「Sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector remained strong, resulting in higher revenue and operating income. Stock ratio: 33.5% at the end of the previous fiscal year → 39.6% at the end of the current fiscal year; licenses (cumulative): 52,251 at the end of the previous fiscal year → 64,775 at the end of the current fiscal year」
Sales of Ex7 and iNote for the medical sector remained strong, and the stock ratio and cumulative number of licenses increased. - FY2025-H1AdvancedAnnual report
「Sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice iNote" for the medical sector remained strong. From the second half onward, the company will strengthen cooperation with sales partners, reinforce sales of "AmiVoice iNote" to improve the stock ratio, and explore new areas at hospitals and clinics through the medical-sector AmiVoice DX Platform (M-ADP). Licenses (cumulative): 52,715 at the end of the first quarter → 53,123 at the end of the interim period」
Sales of Ex7 and iNote remained strong, and the cumulative number of licenses increased from 52,715 to 53,123. Future initiatives include strengthening sales partners, reinforcing iNote sales and exploring new areas through M-ADP. - FY2024AdvancedAnnual report
「Adopted at 18,229 facilities nationwide, including hospitals, clinics, radiology departments and dispensing pharmacies, as of the end of March 2024」
The number of facilities using voice input products for the medical, pharmacy and nursing care sectors increased to 18,229. In the medical business division, the cumulative number of licenses increased from 49,398 to 52,251. - FY2024-Q3AdvancedAnnual report
「Sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector remained firm. Stock ratio: 35.8% at the end of the second quarter → 48.0% at the end of the third quarter under review; licenses (cumulative): 50,851 at the end of the second quarter → 51,633 at the end of the third quarter under review」
Sales of Ex7 and iNote for the medical sector remained firm, with the stock ratio increasing from 35.8% to 48.0% and the cumulative number of licenses increasing from 50,851 to 51,633. - FY2024-Q2AdvancedAnnual report
「Sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector remained firm. Stock ratio: 41.6% at the end of the first quarter → 35.8% at the end of the second quarter under review; licenses (cumulative): 49,722 at the end of the first quarter → 50,851 at the end of the second quarter under review」
Sales of Ex7 and iNote for the medical sector remained firm, and the cumulative number of licenses increased from 49,722 to 50,851. Meanwhile, the stock ratio declined from 41.6% to 35.8%. - FY2024-Q1AdvancedAnnual report
「The "physicians' workplace reform" beginning in April 2024 requires initiatives to optimize physicians' working hours. Accordingly, demand to improve the productivity of doctors, nurses and other healthcare professionals at hospitals has increased, and the company advanced proposals for its core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector.」
Against the backdrop of the physicians' workplace reform, the company continued proposing Ex7 and iNote. The medical business division's stock ratio increased from 32.0% at the end of the previous fiscal year to 41.6%, and the cumulative number of licenses increased from 49,398 to 49,722. - FY2023-Q3AdvancedAnnual report
「The "physicians' workplace reform" beginning in April 2024 requires initiatives to optimize physicians' working hours. Accordingly, demand to improve the productivity of doctors, nurses and other healthcare professionals at hospitals has increased, and the company advanced proposals for its core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector. In addition, AI voice recognition AmiVoice was installed in NEXUS, Fujifilm Medical Co., Ltd.'s endoscopy information management system. Stock ratio: 35.7% at the end of the second quarter → 37.0% at the end of the third quarter under review; licenses (cumulative): 47,369 at the end of the second quarter → 48,040 at the end of the third quarter under review」
Against the backdrop of the physicians' workplace reform, the company continued proposing Ex7 and iNote, and AmiVoice was installed in Fujifilm Medical's NEXUS system. The stock ratio increased from 35.7% to 37.0%, and the cumulative number of licenses increased from 47,369 to 48,040. - FY2023-Q2AdvancedAnnual report
「The "physicians' workplace reform" beginning in April 2024 requires initiatives to optimize physicians' working hours. Accordingly, demand to improve the productivity of doctors, nurses and other healthcare professionals at hospitals has increased, and the company advanced proposals for its core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector.」
Against the backdrop of the physicians' workplace reform beginning in April 2024, the company advanced proposals for the Ex7 series and iNote to medical institutions. The cumulative number of licenses reached 47,369. - FY2023-Q1AdvancedAnnual report
「The "physicians' workplace reform" beginning in April 2024 requires initiatives to optimize physicians' working hours. Accordingly, demand to improve the productivity of doctors, nurses and other healthcare professionals at hospitals has increased, and the company advanced proposals for its core product, the "AmiVoice® Ex7" series of AI voice input software, and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector. Stock ratio: 26.9% at the end of the previous fiscal year → 43.4% at the end of the first quarter under review; licenses (cumulative): 46,217 at the end of the previous fiscal year → 46,829 at the end of the first quarter under review」
Against the backdrop of the physicians' workplace reform beginning in April 2024, the company advanced proposals for the Ex7 series and iNote, and the medical business division's stock ratio and cumulative number of licenses increased. - FY2022AdvancedAnnual report
「Adopted at 15,911 facilities nationwide, including hospitals, clinics, radiology departments and dispensing pharmacies, as of the end of March 2022」
The number of facilities using voice input products for the medical, pharmacy and nursing care sectors increased from 14,654 as of the end of March 2021 to 15,911. - FY2022-Q3AdvancedAnnual report
「In the same quarter of the previous year, revenue and operating income declined due to restrictions on sales activities at medical institutions stemming from the impact of COVID-19. In the current period, in addition to the easing of those restrictions, growing demand to improve the productivity of doctors, nurses and other healthcare professionals at hospitals drove strong sales of the company's core product, the "AmiVoice® Ex7" series of AI voice input software, resulting in year-on-year increases in revenue and operating income. Stock ratio: cumulative 31.9% at the end of the third quarter of the previous fiscal year → cumulative 30.2% at the end of the third quarter under review」
Restrictions on sales activities at medical institutions were eased, and strong sales of the Ex7 series resulted in year-on-year increases in revenue and operating income. Meanwhile, the stock ratio declined from 31.9% to 30.2%. - FY2022-Q2AdvancedAnnual report
「The company also began selling "AmiVoice® iNote Lite," a service supporting record creation at medical facilities using voice input.」
As part of expanding its medical products and services, the company began selling AmiVoice iNote Lite, a service supporting record creation at medical facilities. The resumption of sales activities at medical institutions also contributed to substantial year-on-year increases in revenue and operating income. - FY2022-Q1AdvancedAnnual report
「In the same quarter of the previous year, revenue and operating income declined substantially because sales activities at medical institutions were restricted due to the impact of COVID-19. In the first quarter under review, although the impact persisted, sales activities gradually resumed, resulting in substantial year-on-year increases in revenue and operating income. Stock ratio: 22.8% at the end of the previous fiscal year → 29.7% at the end of the first quarter under review」
Sales activities at medical institutions gradually resumed, and results shifted from lower revenue and operating income in the same quarter of the previous year to higher revenue and operating income. The stock ratio also rose from 22.8% to 29.7%. - FY2021AdvancedAnnual report
「Against this backdrop, the company began proposing the use of services including "AmiVoice® IC-Support," a service that uses "AmiVoice® Ex7/声マウス" and the high-performance 2-channel microphone "AmiVoice® Front FF01" to transcribe conversations between healthcare professionals and patients in real time and with high accuracy across diverse consultation formats, including in-person consultations, in-person medication guidance, online consultations, and telephone consultations and advice, as a voice RPA service for the medical sector using AI voice recognition. The services had been adopted at 14,654 facilities nationwide, including hospitals, clinics, radiology departments and dispensing pharmacies, as of the end of March 2021.」
The company began proposing new medical products and services, including Ex7/声マウス, Front FF01 and IC-Support, bringing the number of facilities using its medical voice input products to 14,654. - FY2021-Q3AdvancedAnnual report
「To meet new demand at medical institutions arising from COVID-19, the company enhanced the functions of its AI voice input software "AmiVoice® Ex7" and planned and developed new products and services using AI voice recognition AmiVoice®. Against this backdrop, it began selling "AmiVoice® OAM (Online Assist for Medical)," a cloud service supporting in-person and online consultations as a voice RPA service for the medical sector using AI voice recognition.」
For the medical sector, the company enhanced Ex7's functions and developed new products and services, and began selling OAM, which supports in-person and online consultations. Meanwhile, revenue and operating income declined substantially due to restrictions on sales activities. - FY2021-Q2SoftenedAnnual report
「Although demand for efficient data entry and document preparation using AI voice recognition AmiVoice® remained strong as workplace reform initiatives spread at hospitals, revenue and operating income declined substantially because sales activities at medical institutions were restricted due to the impact of COVID-19.」
Although demand in the medical sector remained strong, revenue and operating income declined substantially due to restrictions on sales activities at medical institutions, weakening progress in sales expansion. - FY2021-Q1AdvancedAnnual report
「The iOS voice input keyboard app "AmiVoice® SBx Medical" for the medical and nursing care sectors was installed as a standard feature in Care Palette, ND Software Co., Ltd.'s nursing care ICT software.」
SBx Medical added a new adoption case through its standard installation in the nursing care ICT software Care Palette. Meanwhile, the medical business posted a substantial decline in revenue due to restrictions on sales activities at medical institutions. - FY2020AdvancedAnnual report
「As part of efforts to improve the productivity of doctors, nurses and other healthcare professionals at hospitals, the company promoted sales and adoption of products including the "AmiVoice® Ex7" series of AI voice input software, the mobile AI voice input service "AmiVoice® SBx Medical" and the work-sharing service "AmiVoice iNote®" to meet demand for efficient medical-record entry and the preparation of forms and reports.」
The company promoted sales and adoption of Ex7, SBx Medical and iNote, bringing the number of medical facilities using its products to 13,836 as of 31 March 2020. - FY2020-Q3RestatedAnnual report
「As part of efforts to improve the productivity of doctors, nurses and other healthcare professionals at hospitals, the company promoted sales and adoption of products including the "AmiVoice® Ex7" series of AI voice input software, the mobile AI voice input service "AmiVoice® SBx Medical" and the work-sharing service "AmiVoice® iNote" to meet demand for efficient medical-record entry and the preparation of forms and reports.」
The company continues to pursue its policy of promoting sales and adoption of Ex7, SBx Medical and iNote for the medical sector. - FY2020-Q2AdvancedAnnual report
「The company also promoted sales and adoption of mobile versions of the iOS AI voice input keyboard app "AmiVoice® SBx Medical" and the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector.」
The company promoted sales and adoption of mobile versions of SBx Medical and iNote for the medical sector and continued rolling out the products and services. - FY2020-Q1RestatedAnnual report
「As the spread of workplace reform initiatives at hospitals increased demand for efficient data entry and document preparation, sales of licenses for existing products remained firm. License sales to sales and development partners for products for dispensing pharmacies also remained firm.」
In the medical and pharmacy sectors, license sales of existing products and license sales to sales and development partners for products for dispensing pharmacies remained firm. - FY2019AdvancedAnnual report
「The company expanded its product lineup of apps and services by releasing "AmiVoice® SBx Medical," an iOS AI voice input keyboard app for the medical sector that covers a comprehensive range of medical terminology and enables voice input in any application without integration, and beginning sales of the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector.」
The company expanded its medical products and services by releasing SBx Medical and launching sales of iNote. The medical business posted a 2.5% year-on-year increase in revenue, while products for dispensing pharmacies fell short of the initial plan. - FY2019-Q3AdvancedAnnual report
「The company began selling the AI voice recognition work-sharing service "AmiVoice® iNote" for the medical sector in October. It also secured substantial license revenue from an OEM partner for products for dispensing pharmacies.」
The company confirmed the launch of sales of AmiVoice iNote for the medical sector and secured substantial license revenue from an OEM partner for products for dispensing pharmacies. - FY2019-Q2AdvancedAnnual report
「The company advanced development of the AI voice recognition work-sharing service "AmiVoice iNote" for the medical sector, which began sales in October, and expanded its products and services to improve the efficiency of data entry and other operations at hospitals. However, sales of products for dispensing pharmacies declined year on year, resulting in lower revenue for the business division as a whole.」
The company began selling and developing the AI voice recognition work-sharing service AmiVoice iNote for the medical sector, expanding its products and services. Meanwhile, revenue from products for dispensing pharmacies declined year on year. - FY2019-Q1AdvancedAnnual report
「The company released "AmiVoice® SBx Medical," an iOS voice input keyboard app for the medical sector that covers a comprehensive range of medical terminology and enables voice input in any app without integration. It expanded its product lineup to improve the efficiency of data entry and other operations at hospitals.」
For the medical sector, the company released the iOS voice input keyboard app SBx Medical, which covers a comprehensive range of specialized terminology, and expanded its product lineup. - FY2018AdvancedAnnual report
「The company began selling the cloud-based mobile voice input service "AmiVoice® MLx" and the cloud-based voice input management service "AmiVoice® iVoX Medical," which enables users to make recordings simply by speaking into a smartphone and to create, manage and share records. The company expanded its product lineup for the medical sector, while also promoting sales of existing products, resulting in a 15.1% increase in revenue from the previous fiscal year.」
For the medical sector, the company expanded its product lineup by launching sales of MLx and iVoX Medical, and the medical business posted a 15.1% year-on-year increase in revenue. - FY2018-Q1RestatedAnnual report
「The company pursued a sales partner strategy for the cloud-based voice input service "AmiVoice® CLx" for the medical, pharmacy and nursing care sectors and began selling its mobile service, "AmiVoice® MLx," thereby promoting the monthly subscription model and expanding its product lineup.」
The company continues to pursue the CLx sales partner strategy and promote the monthly subscription model. The launch of MLx sales was recorded as a separate new thread. - FY2017-Q3RestatedAnnual report
「The company also pursued the development of sales partners alongside sales of the cloud-based voice input service "AmiVoice® CLx" for the medical, pharmacy and nursing care sectors.」
The company continues to sell CLx and develop sales partners for the medical, pharmacy and nursing care sectors. - FY2017-Q2RestatedAnnual report
「The company also pursued a partner strategy to expand sales of the cloud-based voice input service "AmiVoice® CLx" for the medical, pharmacy and nursing care sectors.」
The company continues to pursue a partner strategy for its cloud-based voice input service for the medical, pharmacy and nursing care sectors. - FY2017-Q1First statedAnnual report
「The company also pursued a partner strategy to expand sales of the cloud-based voice input service "AmiVoice CLx" for the medical and nursing care sectors.」
A partner strategy is being pursued as a means of expanding sales of cloud services for the medical and nursing care sectors.